{
    "clinical_study": {
        "@rank": "25004", 
        "acronym": "ATOM ES", 
        "arm_group": [
            {
                "arm_group_label": "mFOLFOX + Bmab", 
                "arm_group_type": "Experimental", 
                "description": "mFOLFOX plus bevacizumab"
            }, 
            {
                "arm_group_label": "mFOLFOX + Cmab", 
                "arm_group_type": "Active Comparator", 
                "description": "mFOLFOX plus cetuximab"
            }
        ], 
        "brief_summary": {
            "textblock": "The correlation between the values of angiogenesis-related growth factors in plasma and\n      efficacy, and biomarkers relevant as prognostic factors or predictive factors for\n      sensitivity or resistance to treatment will be examined exploratively."
        }, 
        "brief_title": "Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases", 
        "condition": "Liver Only Metastasis From Colorectal Cancer ( KRAS Wild-type )", 
        "condition_browse": {
            "mesh_term": [
                "Colorectal Neoplasms", 
                "Neoplasm Metastasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "The correlation between the values of angiogenesis-related growth factors in plasma and\n      efficacy, and biomarkers relevant as prognostic factors or predictive factors for\n      sensitivity or resistance to treatment will be examined exploratively."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who registered the ATOM trial and signed informed consent prior to\n             initiation of any trial-specific procedure and treatment.\n\n        Exclusion Criteria:\n\n          -  None"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01834014", 
            "org_study_id": "ATOM Exploratory study", 
            "secondary_id": "UMIN000010429"
        }, 
        "intervention": [
            {
                "arm_group_label": "mFOLFOX + Bmab", 
                "description": "5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.  Liver resection if resectable after 8 cycles or continue until progression of disease.", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug", 
                "other_name": "Avastin"
            }, 
            {
                "arm_group_label": "mFOLFOX + Cmab", 
                "description": "250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle.  Liver resection if resectable after 8 cycles or continue until progression of disease.", 
                "intervention_name": "Cetuximab", 
                "intervention_type": "Drug", 
                "other_name": "Erbitux"
            }, 
            {
                "arm_group_label": [
                    "mFOLFOX + Bmab", 
                    "mFOLFOX + Cmab"
                ], 
                "description": "85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.  Liver resection if resectable after 8 cycles or continue until progression of disease.", 
                "intervention_name": "L-OHP", 
                "intervention_type": "Drug", 
                "other_name": "Oxaliplatin"
            }, 
            {
                "arm_group_label": [
                    "mFOLFOX + Bmab", 
                    "mFOLFOX + Cmab"
                ], 
                "description": "200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.  Liver resection if resectable after 8 cycles or continue until progression of disease.", 
                "intervention_name": "l-LV", 
                "intervention_type": "Drug", 
                "other_name": "Levofolinate"
            }, 
            {
                "arm_group_label": [
                    "mFOLFOX + Bmab", 
                    "mFOLFOX + Cmab"
                ], 
                "description": "400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.  Liver resection if resectable after 8 cycles or continue until progression of disease.", 
                "intervention_name": "5-FU", 
                "intervention_type": "Drug", 
                "other_name": "Fluorouracil"
            }, 
            {
                "arm_group_label": [
                    "mFOLFOX + Bmab", 
                    "mFOLFOX + Cmab"
                ], 
                "description": "2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.  Liver resection if resectable after 8 cycles or continue until progression of disease.", 
                "intervention_name": "5-FU", 
                "intervention_type": "Drug", 
                "other_name": "Fluorouracil"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Bevacizumab", 
                "Cetuximab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "lastchanged_date": "May 6, 2013", 
        "location": {
            "contact": {
                "email": "prj-atomdc@eps.co.jp", 
                "last_name": "Tasumi Shimizu", 
                "phone": "+81-3-5684-7767"
            }, 
            "facility": {
                "address": {
                    "city": "Bunkyo-ku", 
                    "country": "Japan", 
                    "state": "Tokyo", 
                    "zip": "112-0004"
                }, 
                "name": "EPS Corporation"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Exploratory Study to Evaluate Biomarkers as Predictive and /or Prognostic Factors of Benefit From Randomized Phase ll Study of mFOLFOX6+Bevacizumab or mFOLFOX6+Cetuximab in Liver Only Metastasis From KRAS Wild Type Colorectal Cancer", 
        "overall_official": [
            {
                "affiliation": "Graduate School of Comprehensive Human Sciences, Tsukuba University, Department of Gastroenterology", 
                "last_name": "Ichinosuke Hyodo, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Kobe University Graduate School of Medicine, Division of Gastrointestinal Surgery, Department of Surgery", 
                "last_name": "Yoshihiro Kakeji, MD, PhD, FACS", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare of Japan", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the values of angiogenesis-related growth factors in plasma with PFS centrally assessed", 
            "measure": "To evaluate the values of angiogenesis-related growth factors in plasma with Progression-free survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Cycle 8, Progression Disease"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01834014"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Response rate, Tumor shrinkage rate, Liver resection rate, R0 liver resection rate( pathologically confirmed ), Progression-free survival(CT/MRI image assessed by the attending physician), Time to treatment-failure, Overall survival, Incidence of adverse events (drag-related, surgery-related) , Pathological diagnosis; the patients who undergo liver resection", 
                "measure": "To evaluate the correlation of values of angiogenesis-related growth factors in plasma with efficacy and adverse events", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Cycle 8, Progression Disease"
            }, 
            {
                "measure": "Exploratory analysis of the relevance of tumor size and expression level of angiogenesis-related growth factors in plasma", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Cycle 8, Progression Disease"
            }
        ], 
        "source": "EPS Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "EPS Corporation", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}